Hikma acquires the rights to 17 Takeda brands for MENA territories

Ownership of a portfolio of pharmaceutical brands transfers for MENA territories that include North African markets inside Hikma’s footprint.


Coverage: The Meridian legal market record (editorial).

Ownership of a portfolio of pharmaceutical brands transfers for MENA territories that include North African markets inside Hikma's footprint.

Record ID TX-AFR-2024-0047
Record type Commercial IP transaction
Transaction type Trade mark assignment, IP portfolio acquisition, Licence extension
IP rights trade mark, regulatory data
Status Signed
Qualifying date 2024-12-19
Sector Life sciences · Branded pharmaceuticals
African markets Egypt, Morocco
Licensed territory Not separately described in the sources reviewed.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • Hikma Pharmaceuticals PLC (United Kingdom): acquirer, assignee, licensee
  • Takeda Pharmaceuticals International AG (Switzerland): seller, assignor, licensor

Key terms

  • Interest: ownership (assignment of licensed rights); Exclusivity: Ownership in the territories; Territorial scope: Select MENA territories

Sources

  1. Hikma acquires the rights to a portfolio of Takeda brands for the MENA region, Hikma Pharmaceuticals, 2024-12-19

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.